arrow
J

James L.M. Ferrara

Icahn School of Medicine at Mount Sinai
H指数:91
被引数:2.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Performance of treatment response assessment at day 7 by baseline acute graft-vs-host disease severity

基于基线急性移植物抗宿主病严重程度的第7天治疗反应评估表现

2025-09-250
PRE
Refinement of Day 28 Treatment Response Criteria for Acute GVHD: A Collaboration Study of the JSTCT and MAGIC

急性GVHD第28天治疗反应标准的修订:JSTCT与MAGIC的合作研究

2025-07-030
OAAI
Serial Clinical and Biomarker Monitoring during Graft-Versus-Host Disease Treatment Identifies Distinct Risk Strata Including an Ultra-Low Risk Group

移植物抗宿主病治疗期间的系列临床和生物标志物监测确定了不同的风险阶层,包括超低风险组

2025-01-010
PRE
Differences in Acute Graft-Versus-Host Disease (GVHD) Severity and Its Outcomes Between Black and White Patients

黑人和白人患者急性移植物抗宿主病 (GVHD) 严重程度及其结局的差异

2024-11-011
PRE
The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD
2024-06-282
OAAI
Amphiregulin, ST2, and REG3 α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD
2024-06-140
OAAI
A Validated Risk Strati fi cation That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHD

包含神奇生物标志物的经过验证的风险分层可预测急性GVHD患儿的长期预后

2024-06-012
OAAI
Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis
2024-04-233
OAAI
A Day 14 Endpoint for Acute GVHD Clinical Trials
2024-04-012
OAAI
Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease
2023-09-1210
OAAI
The utility of biomarkers in acute GVHD prognostication
2023-08-318
OAAI
Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD
2023-08-1113
OAAI
Reg3? concentrations at day of allogeneic stem cell transplantation predict outcome and correlate with early antibiotic use
2023-04-034
OAAI
Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification
2022-06-2320
OAAI